A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the safety of NeoRecormon in the correction of anemia in
patients with chronic hepatitis C who are being treated with Pegylated interferon + ribavirin
combination therapy. Patients will receive NeoRecormon at a starting dose of 30,000 IU s.c.
which will be adjusted as required to maintain a target Hb of 11-13g/dL. The anticipated time
on study treatment is 1 year, and the target sample size is 100-500 individuals.